🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

AbbVie's Parkinson's disease drug meets main goal in late-stage trial

Published 09/26/2024, 08:07 AM
Updated 09/26/2024, 09:11 AM
© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
ABBV
-

(Reuters) -AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday.

Patients showed a statistically significant improvement when two fixed doses of the drug, tavapadon, as a monotherapy were compared to placebo, as measured on a rating scale.

The Movement Disorder Society - Unified Parkinson's Disease Rating Scale was developed to evaluate various aspects of Parkinson's disease.

The trial enrolled 529 adults between the ages of 40 and 80, who had the disease for less than three years.

The drug also met the secondary goal by showing improvement in motor skills required for daily activities in both 5 mg and 15 mg doses at 26 weeks.

AbbVie (NYSE:ABBV) gained access to the treatment with its $8.7 billion buyout of Cerevel Therapeutics.

Tavapadon is being studied as a once-daily treatment for Parkinson's disease, a nervous system disorder that causes progressive brain damage leading to symptoms that include problems with movement, tremor, stiffness, and impaired balance.

© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

In another late-stage trial, tavapadon improved symptom control in patients when tested as an add-on therapy to levodopa, the standard of care of the disease.

Results from another late-stage trial, studying tavapadon as a flexible-dose monotherapy, is expected by the end of the year, AbbVie said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.